Advances in Clinical Chemistry

1. Auflage 2010
ISBN: 978-0-12-380982-7
Verlag: Elsevier Book Series
Format: PDF
Kopierschutz: Adobe DRM (»Systemvoraussetzungen)

E-Book, Englisch, 232 Seiten

Volume 47 in the internationally acclaimed Advances in Clinical Chemistry contains chapters submitted from leading experts from academia and clinical laboratory science. Authors are from a diverse field of clinical chemistry disciplines and diagnostics, ranging from basic biochemical exploration to cutting-edge microarray technology.
Leading experts from academia and clinical laboratory science Volume emphasizes novel laboratory advances with application to clinical laboratory diagnostics and practical basic science studies

Autoren/Hrsg.

Inhaltsverzeichnis

1;Front Cover;1
2;Advances in Clinical Chemistry;4
3;Copyright Page;5
4;Contents;6
5;Contributors;10
6;Preface;12
7;Chapter 1: Prothrombin Fragments in Cardiovascular Disease;14
7.1;1. Abstract;14
7.2;2. Introduction: Thrombosis and Cardiovascular Disease;15
7.3;3. The Blood Coagulation;16
7.4;4. Markers of Hemostatic Activation;18
7.5;5. F1+2 in Cardiovascular Disease;19
7.6;6. How Can Circulating Levels of F1+2 Be Modulated?;29
7.7;7. Pathophysiological Aspects of Other Prothrombin Fragments;29
7.8;8. Conclusions;29
7.9;Acknowledgments;30
7.10;References;30
8;Chapter 2: Carbamylated LDL;38
8.1;1. Abstract;39
8.2;2. Atherosclerosis in Kidney Disease;39
8.3;3. Chronic Uremia-Induced Atherosclerosis;39
8.4;4. Modified LDLs in Atherosclerosis;41
8.5;5. Uremic Toxins and Protein Carbamylation;42
8.6;6. Plasma Protein Carbamylation and Atherosclerosis;44
8.7;7. LDL Carbamylation: Initial Observations;44
8.8;8. Induction of Proliferation and Death of Cultured Endothelial Cells by cLDL;45
8.9;9. Acceleration of Monocyte Adhesion to Endothelial Cells by cLDL;45
8.10;10. Endothelial cLDL Receptors;46
8.11;11. Effects of cLDL on Cultured Smooth-Muscle Cells;48
8.12;12. In Vivo Properties of cLDL;48
8.13;13. cLDL Assays;49
8.14;14. Human Studies of cLDL;49
8.15;15. Autoantibody to cLDL and Other Modified LDLs;53
8.16;16. Double Modified LDLs;53
8.17;17. Perspectives of Anti-cLDL Therapy;54
8.18;18. Conclusion;55
8.19;References;55
9;Chapter 3: Cocaine in Acute Myocardial Infarction;66
9.1;1. Abstract;66
9.2;2. Structure and Metabolism of Cocaine;67
9.3;3. Epidemiology of Cocaine Abuse;68
9.4;4. Cocaine Testing;69
9.5;5. Toxicity of Cocaine Abuse;72
9.6;6. Cocaine and Chest Pain;73
9.7;7. Should Cocaine Use Be Screened in Patients with Acute Myocardial Infarctions?;76
9.8;8. Conclusions;80
9.9;References;80
10;Chapter 4: EGFR and KRAS in Colorectal Cancer;84
10.1;1. Abstract;85
10.2;2. Introduction;85
10.3;3. EGFR Signal Transduction;86
10.4;4. Monoclonal Antibodies Targeting EGFR;88
10.5;5. Landmark Clinical Trials in the Pre-KRAS Era;90
10.6;6. Predictive Value of EGFR;92
10.7;7. Biology of RAS;92
10.8;8. Prognostic Relevance of KRAS Mutations in Colorectal Cancer;94
10.9;9. Predictive Role of KRAS Status in Colorectal Cancer;95
10.10;10. Testing for KRAS Status;105
10.11;11. BRAF in Colorectal Cancer;108
10.12;12. Predictive Role of BRAF in Colorectal Cancer;109
10.13;13. Alternate Predictive Biomarkers for anti-EGFR Therapies in Colorectal Cancer;111
10.14;14. Future Therapeutic Strategies in Colorectal Cancer;119
10.15;15. Conclusion;124
10.16;References;125
11;Chapter 5: Prostaglandin EP Receptors and Their Roles in Mucosal Protection and Ulcer Healing in The Gastrointestinal Tract;134
11.1;1. Abstract;134
11.2;2. Introduction;135
11.3;3. Gastric Protection;136
11.4;4. Esophageal Protection;143
11.5;5. Duodenal Protection and HCO3- Stimulation;144
11.6;6. Intestinal Protection;147
11.7;7. Healing-Promoting Action;150
11.8;8. Summary and Future Prospects;151
11.9;Acknowledgments;154
11.10;References;154
12;Chapter 6: Advances in Pancreatic Cancer Detection;158
12.1;1. Abstract;158
12.2;2. Introduction;159
12.3;3. Conventional Markers;160
12.4;4. Candidates in Biomarker Discovery;161
12.5;5. Therapy-Related Biomarkers;172
12.6;6. Genomics/Transcriptomics/Proteomics;173
12.7;7. Conclusions;180
12.8;Acknowledgments;181
12.9;References;181
13;Chapter 7: Urine Peptidomics for Clinical Biomarker Discovery;194
13.1;1. Abstract;194
13.2;2. Introduction;195
13.3;3. Urine Peptidome is a Rich Source of Peptides of Diversified Protein Origins;195
13.4;4. Quantitative Urine Peptidomics for Biomarker Discovery;201
13.5;5. Urine Sample Handling and Storage;206
13.6;6. Do ``Housekeeping Peptides´´ Exist in Urine Peptidome?;211
13.7;7. To Pool or Not Pool, Practical Considerations of Benefits, Risks and Biases;213
13.8;8. Multiple Hypothesis Testing, False Discovery, and Bootstrapping Analysis;216
13.9;9. Exploration of Urine Peptide Biomarkers as Predictors of Drug Response;219
13.10;10. Urine Peptidome Proteolytic Degradation Patterns Reflecting Pathophysiology;221
13.11;Acknowledgments;223
13.12;References;223
14;Subject Index;228